Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.37 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.36 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3611410 | 0.99 | RORC (0.36) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| SCHEMBL3608986 | 0.97 | RORC (0.37) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| Hydrochloric Acid SCHEMBL3610550 | 0.97 | RORC (0.37) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| Hydrochloric Acid SCHEMBL3614218 | 0.93 | RORC (0.34) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| SCHEMBL3616236 | 0.91 | RORC (0.39) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| SCHEMBL3613552 | 0.89 | RORC (0.36) | RORCF11ACE | |
| Hydrochloric Acid SCHEMBL3611710 | 0.88 | RORC (0.35) | RORCF11ACE | |
| SCHEMBL3616055 | 0.88 | RORC (0.38) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| SCHEMBL3596093 | 0.88 | RORC (0.36) | RORCSOAT2ACAT1SOAT1MTNR1B | |
| SCHEMBL3612536 | 0.88 | RORC (0.34) | RORCF11ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | RORC 488/4885SOAT2 7/4885ACAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.